C-support Revenue and Competitors
Estimated Revenue & Valuation
- C-support's estimated annual revenue is currently $35.6M per year.
- C-support's estimated revenue per employee is $349,412
Employee Data
- C-support has 102 Employees.
- C-support grew their employee count by 0% last year.
C-support Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $26.7M | 79 | 3% | N/A | N/A |
#2 | $83.5M | 232 | 6% | N/A | N/A |
#3 | $35.9M | 133 | 23% | N/A | N/A |
#4 | $198.1M | 524 | 7% | N/A | N/A |
#5 | $23M | 71 | 8% | N/A | N/A |
#6 | $49.9M | 173 | 14% | N/A | N/A |
#7 | $68.6M | 185 | 3% | N/A | N/A |
#8 | $199.1M | 471 | 3% | N/A | N/A |
#9 | $60.9M | 182 | 6% | N/A | N/A |
#10 | $28.1M | 79 | -2% | N/A | N/A |
What Is C-support?
C-support is er voor patiënten die langdurig klachten ondervinden van Covid-19. C-support ondersteunt op alle leefgebieden waarop deze complexe en onbekende ziekte ingrijpt en biedt maatwerk.
keywords:N/AN/A
Total Funding
102
Number of Employees
$35.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
C-support News
2022-04-17 - China central bank pledges to support economy amid crippling ...
"China's monetary policy is accommodative and is in a comfortable range. We also stand ready to support small and medium-sized enterprises with...
2022-04-17 - Hepatitis C: Recognizing and Addressing the Stigma
And even if someone is exposed to the virus through drug use, they're deserving of support, not judgment. People who've used drugs face...
2022-04-17 - Historic inflection point' for cultivated meat: UPSIDE Foods closes ...
Historic inflection point' for cultivated meat: UPSIDE Foods closes $400m series C round to support commercial-scale plant with production...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 102 | 0% | N/A |
#2 | $3.5M | 104 | 24% | N/A |
#3 | N/A | 105 | 25% | N/A |
#4 | $27.3M | 123 | 27% | N/A |
#5 | N/A | 133 | 20% | N/A |